NOV 16, 2020 7:00 AM PST

Hepatitis B. The added value of an accurate diagnosis for the optimization of the patients clinical management

Sponsored by: DiaSorin
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor of Virology at the Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Italy
    Biography
      Valentina Svicher is an Associate Professor of Virology at the Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata". She got a degree cum laude in Biological Sciences in 2001 and a PhD in Microbiology and Immunology in 2006. Her research interests and expertise are focused on mechanisms underlying pathogenesis and response to therapy in the setting of chronic viral infections with particular attention on hepatitis B and D virus.
      She is author of more than 90 full papers in peer-reviewed journals, and more than 250 papers presented at numerous National and International Conferences. She received several awards such as "GB Rossi" Scientific Prize 2009, "Readfiles" Scientific Award 2008 and the Scientific Award "Infection Lab 2016" for the best scientific publications or projects in the infectivology field.
      She collaborates with many nationally and internationally recognized scientific researchers through grants from the Italian National Institute of Health, the Ministry of University and Scientific Research, the European Community and Industrial Companies.
      She is member of the Board of the Scientific Society "European Society for Antiviral Research (ESAR); Member of the HCV Italian Resistance Network Study Group; Member of the European HepCare group; Member of the Italian Study Group on the treatment and prophylaxis of HBV in the haematological patients.

    Abstract

    Date:  November 16, 2020

    Time: 7:00am PDT

     

    So far, it has been estimated that 2 billion individuals have been infected by hepatitis B virus (HBV). Among them, 250 million have developed a chronic infection and are at risk to develop cirrhosis and hepatocellular carcinoma. Every year, 1 million individuals die for these end-stage liver diseases. Nevertheless, these numbers are considered an underestimation and this is mainly due to the lack of adequate HBV screening programmes. Despite the availability of an effective vaccine, chronic HBV infection still remains an important driver of hepatocarcinogenesis. In endemic areas for HBV, 70-80% cases of liver cancer are caused by this virus.

    In this light, the availability of an accurate armamentarium of HBV biomarkers is crucial for a proper diagnosis of HBV infection and in turn for a prompt retention in care of HBV infected patients pivotal slow down disease progression.

    In this light, this webinar will be aimed at strengthening the importance of a proper and timely diagnosis of HBV infection, and at highlighting the role of classical and innovative biomarkers (such as quantitative serum HBsAg and quantitative serum HBeAg) in optimizing the management of patients with HBV infection.

     

    Learning Objectives:

    • Strengthening the importance on an accurate HBV diagnosis for a prompt retention in care of patients with HBV infection 
    • Understanding the diagnostic and clinical relevance of HBV biomarkers 
    • Describing the clinical relevance of quantitative HBsAg and HBeAg

     

     

    Webinars will be available for unlimited on-demand viewing after live event.

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    APR 21, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more